A Phase 2 Study of Dasatinib in Patients With Transplant and Non-Transplant Related Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma and RAI Stage 0-1 Chronic Lymphocytic Leukemia
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Dasatinib (Primary)
- Indications Skin cancer
- Focus Biomarker; Therapeutic Use
- 18 Jun 2015 Biomarkers information updated
- 18 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Jul 2012 Planned End Date changed from 1 Nov 2008 to 1 Jan 2100 as reported by ClinicalTrials.gov.